Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcription factor
BCL11B
/CTIP2 is a major regulatory protein implicated in various aspects of development, function and survival of T cells. Mitogen-activated protein kinase (MAPK)-mediated phosphorylation and SUMOylation modulate
BCL11B
transcriptional activity, switching it from a repressor in naive murine thymocytes to a
transcriptional activator
in activated thymocytes. Here, we show that
BCL11B
interacts via its conserved N-terminal MSRRKQ motif with endogenous MTA1 and MTA3 proteins to recruit various NuRD complexes. Furthermore, we demonstrate that protein kinase C (PKC)-mediated phosphorylation of
BCL11B
Ser2 does not significantly impact
BCL11B
SUMOylation but negatively regulates NuRD recruitment by dampening the interaction with MTA1 or MTA3 (MTA1/3) and RbAp46 proteins. We detected increased phosphorylation of
BCL11B
Ser2 upon in vivo activation of transformed and primary human CD4(+) T cells. We show that following activation of CD4(+) T cells,
BCL11B
still binds to IL-2 and Id2 promoters but activates their transcription by recruiting P300 instead of MTA1. Prolonged stimulation results in the direct transcriptional repression of
BCL11B
by KLF4. Our results unveil Ser2 phosphorylation as a new
BCL11B
posttranslational modification linking PKC signaling pathway to T-cell receptor (TCR) activation and define a simple model for the functional switch of
BCL11B
from a transcriptional repressor to an activator during TCR activation of human CD4(+) T cells.
...
PMID:Protein Kinase C-Mediated Phosphorylation of BCL11B at Serine 2 Negatively Regulates Its Interaction with NuRD Complexes during CD4+ T-Cell Activation. 2716 21
The initial stages of T-cell differentiation are characterized by a progressive commitment to the T-cell lineage, a process that involves the loss of alternative (myelo-erythroid, NK, B) lineage potentials. Aberrant differentiation during these stages can result in T-cell acute lymphoblastic leukemia (T-ALL). However, the mechanisms regulating the initial stages of human T-cell differentiation are obscure. Through loss of function studies, we showed
BCL11B
, a transcription factor recurrently mutated T-ALL, is essential for T-lineage commitment, particularly the repression of NK and myeloid potentials, and the induction of T-lineage genes, during the initial stages of human T-cell differentiation. In gain of function studies,
BCL11B
inhibited growth of and induced a T-lineage transcriptional program in T-ALL cells. We found previously unknown differentiation stage-specific DNA binding of
BCL11B
at multiple T-lineage genes; target genes showed
BCL11B
-dependent expression, suggesting a
transcriptional activator
role for
BCL11B
at these genes. Transcriptional analyses revealed differences in the regulatory actions of
BCL11B
between human and murine thymopoiesis. Our studies show
BCL11B
is a key regulator of the initial stages of human T-cell differentiation and delineate the
BCL11B
transcriptional program, enabling the dissection of the underpinnings of normal T-cell differentiation and providing a resource for understanding dysregulations in T-ALL.
...
PMID:The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation. 2823 44